ELIRAN MOR

 All content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

 Only those manuscripts which are original, have not been published elsewhere, and are not currently being considered for inclusion in another publication will be considered for publication in Fertility and Sterility®. Authors are advised to keep a copy of all manuscripts submitted.

 All manuscripts will be evaluated by peer reviewers who will remain anonymous. Selection of the peer reviewers is at the sole discretion of the Fertility and Sterility® editors. The editors and reviewers do not disclose any information about a manuscript or its review. If revisions are required, authors are asked to return the revised manuscripts within 30 days for the first revision, and within 20 days for any subsequent revisions. Please notify the editorial office if additional time is needed or if you choose not to submit a revision.

 Conditions of Authorship. Authors should have made significant conceptual, intellectual, experimental, and analytical contributions to the research, as well as having participated in writing and revising the manuscript. Each author should have participated sufficiently in the work to take public responsibility for its content. Honorary authorship (i.e., not adhering to the conditions of authorship and, none-the-less, being granted authorship) is not permitted.

 Responsibilities of Authors. Authors must describe the research in sufficient detail such that others could repeat it. Written, informed consent under protocols approved by an institutional or local review board or approved animal protocols are essential if the research involves human or animal subjects, respectively. This information should be stated in the manuscript and the protocol number or exempt status of approved protocols should be stated in the manuscript at the time of submission for review. Authors of clinical trials are required to prospectively register their trial with one of the ICMJE-recognized trial registries . Selective reporting of data is inappropriate, especially if unreported data are in disagreement with the findings of the selectively reported data. In accordance with the ICJME, the ASRM supports publication of negative studies. Authors should cite publications in the literature that are relevant to the uniqueness of the research and should including publications by others, as well as of their own research group. Previous publication of a preliminary report on the data is permissible, if this is stated clearly in a footnote in the manuscript.

 For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy (here) includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; and Writing - review and editing. Note that not all roles may apply to every manuscript, and authors may have contributed through multiple roles. More details and an example.

 Changes to authorship. Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

 Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

 Scientific Misconduct. The DHHS Office of Research Integrity defines plagiarism, fabrication, and falsification. The ASRM accepts these definitions and considers them to constitute scientific misconduct. Additional unethical behavior that comprises scientific misconduct includes: submission of results from animal or clinical research that was conducted without appropriate approval and written, informed consent; duplicate publication; and honorary authorship. Research misconduct occurs when results are falsified, fabricated or plagiarized. The actions are willful or intentional, although the actual definition of misconduct varies somewhat by country. This can occur at various times during the process of proposing, performing or reviewing research. Differences of opinion or honest errors do not constitute misconduct.

 Plagiarism: Using another person's words, ideas, results, and processes without giving credit to them. Plagiarism includes the theft of intellectual property, ideas or methods such as the use of information gained by personal communication, or during a grant or manuscript review. Plagiarism also includes the direct textual copying of another person's work. Direct copying of 100-250 words constitutes plagiarism. Authorship disputes are not included in this definition. Citation plagiarism is the failure to credit others with prior discoveries and is extremely common. Self-plagiarism can include multiple publications of the same manuscript in different journals or books.

 Salami Publications: Dividing data, analysis, and presentation into "minimally publishable units" is a slippery slope, and can be used to extend one data set over several manuscripts. While this may be acceptable for clarity of presentation and focus on specific outcomes in different manuscripts, a motivation may also be to increase the publication list in an author's CV. The latter is unethical and unacceptable. Therefore, please acknowledge in your cover letter any similar publications or submitted manuscripts.

 Partial publication. Partial presentation of data in another medium (e.g., on a website) does not necessarily preclude publication in Fertility and Sterility, but acknowledgment of the previous presentation is required, along with identification of the source (e.g., the URL of the website). Content cannot be copied verbatim from the previous presentation, as that would constitute self-plagiarism, but must be rewritten to comply with journal standards.

 Authors must declare the use of generative AI in scientific writing upon submission of the paper. The following guidance refers only to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process:

 The technology must be applied with human oversight and control and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. Authors are ultimately responsible and accountable for the contents of the work.

 The use of generative AI and AI-assisted technologies in scientific writing must be declared by adding a statement at the end of the manuscript when the paper is first submitted. The statement will appear in the published work and should be placed in a new section before the references list. An example:

 Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.

 Please note: to protect authors' rights and the confidentiality of their research, this journal does not currently allow the use of Generative AI or AI-assisted technologies such as ChatGPT or similar services by reviewers or editors in the peer review and manuscript evaluation process. We are actively evaluating compliant AI tools and may revise this policy in the future.

 Investigation of scientific misconduct. All cases of suspected misconduct will be investigated initially by the Editor-In-Chief and the Publications Committee of the American Society for Reproductive Medicine to determine if the evidence of misconduct is sufficient to proceed with a formal inquiry. If so, the author will be notified in writing of the allegations, and will be asked to provide information useful to the investigation, including access to all original data, notes, and copies of prior publications. The author's institution may be contacted, as well. Processing and publication of the manuscript will be delayed while the matter is resolved. Confidentiality will be maintained and care taken to protect the rights and reputations of all concerned. The final decision on disposition of the paper and any sanctions against the author will be made by the Editor-In-Chief in concert with the Publications Committee.

 Potential sanctions include, but may not be limited to: rejection of a manuscript in process; a letter of reprimand to the author, copied to the author's institution; and correction or retraction of the manuscript, including a statement in the print issue detailing the nature of the misconduct.

Dr Eliran Mor

 Reviewers have the responsibility to objectively and fairly review the manuscript. If there is a conflict of interest or if the reviewer does not have the requisite expertise, then the manuscript should be immediately returned to the Editor for reassignment. Strict confidentiality is required during the review process. If any portion of a manuscript is shared before the review is completed and before acceptance and publication, written consent of the authors is required.

 Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright- holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

 Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

 The cover letter should state that the material contained in the manuscript has not been published, has not been submitted, or is not being submitted elsewhere for publication. Each author's role in the manuscript should be detailed, and any other persons who contributed to the manuscript (providing writing assistance, for example) should be disclosed. Please note in the cover letter any manuscripts that have been published, submitted, or are in press that are similar to the submission to Fertility and Sterility and include in your submission copies of these so that the editors can be assured that there is no overlap. All authors' agreement to submission of the manuscript should be noted.

 Author names and affiliations: Please include each author's full name and highest earned academic degree(s). Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliations below the names. Include the department (if applicable), institution name, city, and state/country. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate affiliation. If an author's affiliation has changed since the work was done, the new affiliation also should be listed.

 Corresponding author: Only one corresponding author may be designated. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.

 Disclosure Statement: In the interest of transparency, we ask you to disclose all relationships/activities/interests that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

 The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to stimulation for ART, you should declare all relationships with manufacturers of such medication, even if that medication is not mentioned in the manuscript. All authors must disclose any financial and personal relationships with other people or organizations that could influence the design, conductor or reporting of their work. Report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no competing interests, then please state this for each author: Disclosure: "none'.

 All authors are required to report potential conflicts of interest on the title page of the manuscript. The Conflict of Interest form can be found at: ICMJE | Disclosure of Interest. The full form for all authors is required at revision and not submission.

 CRediT Authorship Contribution Statement: List each author and their role in the paper choosing from the following options: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

 Authors need to identify what will be will be made available to others (i.e. the raw data, individual patient data, a data dictionary that defines each field in the data set, and supporting documentation such as statistical/analytic code). If data will be shared, information on when, where, and how the data will be available (eg, a link to a data repository) and if there will be any restrictions on the use of the data. Authors also have the option to explain why data may not be shared. For more information and examples of data sharing statements, please see the ICMJE data sharing guidelines.

 A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations. The target word limit for the abstract is 350 words. Do not include abbreviations, acronyms or commercial names in the abstract.

 The structured abstract for all study types except systematic reviews should include the sections: Objective (beginning with a phrase like "To study..."), Design, Subjects, Intervention (for RCT) or Exposure (for observational studies), Main Outcome Measures, Results, and Conclusion.

 Immediately after the abstract, provide 3–5 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

 The word limit for the text is 3,500 words. Authors are strongly encouraged to limit article length to 3,500 words for effective and efficient communication. Article length does not include the running title, cover page, capsule, abstract, or references. Only standard medical acronyms should be used and defined with the first use. Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

 A clinical trial is a research project that prospectively and randomly assigns human participants to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. Interventions include but are not limited to drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. Trials must be prospectively registered, prior to patient enrollment, in a publicly accessible database such as clinicaltrials.gov.

 There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

 This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

 To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online.

 Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

 All content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

 All content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

 Draws on 130 interviews---with scientists, clinicians, and women who have either donated or frozen their oocytes or received those of another woman---to trace how the history of human oocytes' perceived value intersects with the biological and social life of women.

 Drawing on theories and concepts across medical sociology and parenting culture studies, as well as literature from demography, anthropology, law, and bioethics, this book examines women's motivations and experiences of social egg freezing in the context of debates surrounding reproductive choice and delayed motherhood.

 Presents the first holistic analysis of PGD and PGS as it is practiced and regulated worldwide. In addition to scientific and technical aspects, the book provides perspectives on the ethical, legal, religious, policy and social implications of global assisted reproduction technologies.

 This tells the story of doctors, researchers, and hopeful couples who pushed the limits of science and triggered a technological revolution in human reproduction. In so doing, they landed at the center of a controversy whose reverberations continue to this day.

 In the United States, some 10% of people who wish to have children struggle with infertility. NOVA explores barriers to fertility, from the social to the biological, and the state of assisted reproductive technologies. Follow the journeys of people navigating challenges from structural inequalities and racism to falling sperm counts, egg freezing, and IVF.

 To examine the psychological impact of fertility treatment suspensions resulting from the COVID-19 pandemic and to clarify psychosocial predictors of better or worse mental health. 92 women from Canada and the United States (ages 20-45 years) whose fertility treatments had been cancelled were recruited via social media. Participants completed a battery of questionnaires assessing depressive symptoms, perceived mental health impact, and change in quality of life related to treatment suspensions. Potential predictors of psychological outcomes were also examined, including several personality traits, aspects of social support, illness cognitions, and coping strategies.

 Infertility is a condition that affects nearly 30 percent of women aged 25–44 in the United States. Though past research has addressed the stigmatization of infertility, few have done so in the context of stigma management between fertile and infertile women. In order to assess evidence of felt and enacted stigma, we employed a thematic content analysis of felt and enacted stigma in an online infertility forum, Fertile Thoughts, to analyze 432 initial threads by women in various stages of the treatment-seeking process.

 In an effort to place the recent Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report publications regarding conception options for mixed-status couples with human immunodeficiency virus (HIV) in perspective, the researchers review the historical evolution of conception options for mixed-status couples with HIV with particular focus on the potential need for fertility treatment and the feasibility of accessing such treatment.

 Are you trying to get pregnant? You might wonder whether there's anything you can do to make it easier to conceive. Some things might be beyond your control or need medical help. These include medical issues that affect being able to conceive. But your lifestyle choices can affect fertility too. Here's what you need to know.

 Female fertility is being able to get pregnant. Have you and your partner been trying to get pregnant by having sex without birth control for at least one year with no success? Not getting pregnant in that time might make you wonder how fertile you are. Anyone can be affected by fertility concerns or problems.

 Trouble releasing eggs, called ovulating, or trouble with regular periods. Hormone-related conditions can affect the release of eggs from the ovaries. These conditions include polycystic ovary syndrome, high prolactin hormone levels and thyroid conditions. Other conditions that may change ovulation or periods are poorly controlled diabetes and some autoimmune diseases such as lupus.

 Aging. Waiting to try to get pregnant can lower the chance of being able to conceive. As you move closer to your 40s, you lose eggs at a faster rate. And the eggs you have are less likely to become fertile.

 Try not to work the night shift. Working the night shift all the time might affect your hormone levels. This can raise the risk of not being fertile. If you do work the night shift, try to get enough sleep when you're not working.

Eliran Mor

 Stress isn't likely to keep you from getting pregnant. But stress isn't good for your health. Think about ways to lower stress. Try meditation, deep breathing, yoga or other activities to lower and manage stress when you try to conceive.

 Limit or avoid alcohol when trying to conceive. Heavy drinking is linked with an higher risk of problems ovulating. To help when you're trying to get pregnant, stop drinking alcohol. Not drinking is the best choice when you conceive and during pregnancy.

 Don't exercise too hard or too long. For people at a healthy weight, too much hard exercise can affect ovulating and lower levels of the hormone progesterone. If you want to become pregnant soon, think about limiting hard exercise, such as running or fast cycling, to less than five hours a week and less than 60 minutes a day.

 Avoid toxins. There are many toxins in the environment. These include pesticides, dry-cleaning solvents and lead. They can harm fertility. Be aware of these toxins and discuss ways to limit exposure to them with a member of your healthcare team.

 STUDY QUESTION Is there evidence of a plateau in the cumulative live birth rate (cLBR) after a certain number of consecutive transfers of untested embryos? SUMMARY ANSWER In our cohort of 11 463 women, the cLBR continues to increase with each additional transfer of an untested embryo, reaching 68.3% after six blastocyst ...

 STUDY QUESTION Can a video clip detailing the patient journey decrease women’s anxiety on the day of their first oocyte retrieval? SUMMARY ANSWER The video clip does not affect women’s anxiety on the day of their first oocyte retrieval. WHAT IS KNOWN ALREADY IVF triggers anxious reactions in women and men, with peaks of ...

 STUDY QUESTION Do serum estradiol (E2) levels on the day of frozen blastocyst transfer (FBT) affect pregnancy outcomes in hormonal replacement therapy (HRT) cycles using transdermal estrogens? SUMMARY ANSWER E2 levels ≥313 pg/ml on the day of FBT are associated with increased early miscarriage rates (EMRs), but do not ...

 STUDY QUESTION Is semen quality associated with the lifespan of men? SUMMARY ANSWER Men with a total motile sperm count of >120 million could expect to live 2.7 years longer than men with total motile sperm count of >0–5 million. WHAT IS KNOWN ALREADY Male infertility and semen quality have been suggested to be ...

 STUDY QUESTION Does the intravenous administration of Atosiban around the time of frozen blastocyst transfer to reduce uterine contractility increase the likelihood of live birth in individuals undergoing ART treatment? SUMMARY ANSWER In individuals with a history of one previous implantation failure, Atosiban did not ...

 STUDY QUESTION Does the objective and quantitative assessment of uterine tissue stiffness via ultrasound shear wave elastography (SWE) predict the outcome after single euploid frozen embryo transfer (FET)? SUMMARY ANSWER Uterine SWE data might be predictive of clinical pregnancy in good prognosis patients undergoing single ...

 STUDY QUESTION Could real-time monitoring of volatile organic compounds (VOCs) in the embryology laboratory provide meaningful early warning for potential harm from the environment? SUMMARY ANSWER Even in a laboratory environment with a total VOC concentration lower than the recommendation of the Cairo Consensus, the ...

 STUDY QUESTION How does two-consecutive single embryo transfer (2xSET) affect reproductive outcomes of IVF and ICSI compared to double embryo transfer (DET)? SUMMARY ANSWER Two-consecutive SET may provide greater or comparable live birth rate (LBR); with lower multiple birth, preterm birth, and pregnancy loss or neonatal ...

 STUDY QUESTION Can a large-scale genome-wide association study (GWAS) meta-analysis identify genomic risk loci and likely involved genes for female genital tract (FGT) polyps, provide insights into the biological mechanism underlying their development, and inform of potential overlap with other traits, including ...

 STUDY QUESTION How does the burden of somatic disorders compare between women with surgically verified endometriosis diagnosed in adolescence or early adulthood, and matched women without a history of endometriosis? SUMMARY ANSWER Women with endometriosis diagnosed at a young age had a higher incidence of several somatic ...

 Oxford University Press uses cookies to enhance your experience on our website. By selecting ‘accept all’ you are agreeing to our use of cookies. You can change your cookie settings at any time. More information can be found in our Cookie Policy.

 Fertility counseling for transgender and gender diverse (TGD) people is a crucial aspect of their healthcare journey, since puberty suppression (PS) induced by a gonadotropin-releasing hormone (GnRH) agonist, gender affirming hormone treatment (GAHT) using testosterone or estrogen and an anti-androgen, and gender affirming surgery (GAS) affect the reproductive function. Fertility counseling can help individuals to make informed decisions about their reproductive goals and options, including options for preserving fertility. By providing comprehensive fertility counseling, healthcare providers can support the reproductive autonomy and overall well-being of TGD people.